Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML

Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.

31 Oct 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing.

20 Sep 2011

Researchers discover new genetic defect that predisposes people to leukemia, myelodysplasia

A new genetic defect that predisposes people to acute myeloid leukemia and myelodysplasia has been discovered. The mutations were found in the GATA2 gene. Among its several regulatory roles, the gene acts as a master control during the transition of primitive blood-forming cells into white blood cells.

5 Sep 2011

Research shows numerous health benefits of Modified Citrus Pectin

New research published in the journal BMC Complementary and Alternative Medicine shows Modified Citrus Pectin (MCP) packs a powerful immune punch.

31 Aug 2011

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.

25 Aug 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

Scientists demonstrate how Modified Citrus Pectin enhances immune function

Groundbreaking research demonstrates the ability of a specific form of Modified Citrus Pectin (MCP) to greatly enhance immune function.

16 Aug 2011

ARIAD reports $47.8 million net loss for second quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

2 Aug 2011

NanoString introduces new assay for leukemia fusion gene analysis

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.

From NanoString Technologies 29 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Indirubin might help treat glioblastoma

The active ingredient in a traditional Chinese herbal remedy might help treat deadly brain tumors, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

13 Jul 2011

Common cell pathway could lead to new treatments for autoimmune diseases and cancer

A discovery by University of Alabama at Birmingham researchers about a how a common cell pathway that helps regulate cell survival and production is turned on could lead to new treatments for autoimmune diseases and cancer.

8 Jul 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Placental growth factor also plays a role in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.

15 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011